THE OBJECTIVE OF THE WORK

Cardiovascular disease area is a vast complicated area with limited scope due to patented technology products in the market. There is no generic formulation available as on date for Dipyridamole Extended release capsules. Hence there is a scope to develop a cost effective generic alternative to these drugs without using costly patented technologies of the innovator & an attempt shall be done to develop a non infringing formulation for any of the selected drug product.

For Dipyridamole MR, the currently available marketed formulation is Aggrenox® ER in USA, Persantin® MR in Europe and Asasantin® SR in Australia. There is no generic formulation available in the market; this is due to complexity of the product which precludes other from developing this product.

This project is aimed at achieving a cost effective quality generic product for the branded formulation of Aggrenox SR. The basic concept for developing this platform technology idea is to use an acidic Solubliser in the formulation in such a way that it will help in improving solubility of pH dependant active in unfavourable pH region. Primary focus would be to develop a non infringing formulation to any existing patents, creating a desired space for the product. The objective of the research work can be focused on developing a pharmaceutically equivalent, bioequivalent , stable , scaleable and commercially viable product.